ArticleScientific reports2021

Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer.

Takashi Ueda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.